Surface guided radiation therapy with an innovative open-face mask and mouth bite: patient motion management in brain stereotactic radiotherapy.

INTRODUCTION: To guarantee treatment reproducibility and stability, immobilization devices are essential. Additionally, surface-guided radiation therapy (SGRT) serves as an accurate complement to frameless stereotactic radiosurgery (SRS) and stereotactic radiotherapy (SRT) by aiding patient positioning and real-time monitoring, especially when non-coplanar fields are in use. At our institute, we have developed a surface-guided SRS (SG-SRS) workflow that incorporates our innovative open-face mask (OM) and mouth bite (MB) to guarantee a precise and accurate dose delivery. METHODS: This study included 40 patients, and all patients were divided into closed mask (CM) and open-face mask (OM) groups according to different positioning flow. Cone beam computed tomography (CBCT) scans were performed, and the registration results were recorded before and after the treatment. Then Bland-Altman method was used to analyze the consistency of AlignRT-guided positioning errors and CBCT scanning results in the OM group. The error changes between 31 fractions in one patient were recorded to evaluate the feasibility of monitoring during treatment. RESULTS: The median of translation error between stages of the AlignRT positioning process was (0.03-0.07) cm, and the median of rotation error was (0.20-0.40)°, which were significantly better than those of the Fraxion positioning process (0.09-0.11) cm and (0.60-0.75)°. The mean bias values between the AlignRT guided positioning errors and CBCT were 0.01 cm, - 0.07 cm, 0.03 cm, - 0.30°, - 0.08° and 0.00°. The 31 inter-fractional errors of a single patient monitored by SGRT were within 0.10 cm and 0.50°. CONCLUSIONS: The application of the SGRT with an innovative open-face mask and mouth bite device could achieve precision positioning accuracy and stability, and the accuracy of the AlignRT system exhibits excellent constancy with the CBCT gold standard. The non-coplanar radiation field monitoring can provide reliable support for motion management in fractional treatment.

Adaptation of contrast injection protocol to tube potential for cardiovascular CT.

OBJECTIVE: The purpose of this study was to investigate and validate adaptation of a cardiovascular CT angiography contrast injection protocol for lower tube potential. MATERIALS AND METHODS: Eighty-three patients evaluated for thoracic aortic disease with a 256-MDCT scanner were imaged at 120 kV (group 1) or 100 kV (group 2) with the same contrast protocol (90 mL iopromide 370 mg I/mL at 3.5 mL/s). A pharmacokinetic model was validated and used to simulate aortic attenuation in group 2 patients with 20%, 33%, and 44% reduction in contrast volume. A 44% volume reduction was applied to 50 additional patients who underwent imaging at 100 kV (group 3). Patient characteristics, scanning and radiation parameters, and objective and subjective image indexes were compared among groups. RESULTS: Group 2 patients had higher mean aortic blood attenuation (399±61 HU) than group 1 patients (281±48 HU) (p<0.001) but similar image noise. Group 3 and group 1 patients had similar mean aortic attenuation and noise. Subjective assessment of image quality indicated that group 3 and group 1 had comparable percentages of images with good or excellent diagnostic confidence scores (reader 1, 98% vs 96%; reader 2, 96% vs 96%). CONCLUSION: Lower tube potential (100 kV) for cardiothoracic CT could be accompanied by a 44% reduction in contrast volume with satisfactory aortic blood-pool attenuation in most patients. More personalized adaptation of the contrast protocol that takes into account patient characteristics and tube potential is necessary to ensure sufficient contrast enhancement for all patients.

Assessment of cardiac function during mechanical circulatory support: the quest for a suitable clinical index.

A new index to assess left ventricular (LV) function in patients implanted with continuous flow left-ventricular assist devices (LVADs) is proposed. Derived from the pump flow signal, this index is defined as the coefficient (k) of the semilogarithmic relationship between "pseudo-ejection" fraction (pEF) and the volume discharged by the pump in diastole, (V d). pEF is defined as the ratio of the "pseudo-stroke volume" (pSV) to V d. The pseudo-stroke volume is the difference between V d and the volume discharged by the pump in systole (V s), both obtained by integrating pump flow with respect to time in a cardiac cycle. k was compared in-vivo with others two indices: the LV pressure-based index, M(TP), and the pump flow-based index, I(Q). M(TP) is the slope of the linear regression between the "triple-product" and end-diastolic pressure, EDP. The triple-product, TP = LV SP.dP/dt(max). HR, is the product of LV systolic pressure, maximum time-derivative of LV pressure, and heart rate. I(Q) is the slope of the linear regression between maximum time-derivative of pump flow, dQ/dt(max), and pump flow peak-to-peak amplitude variation, Q(P2P). To test the response of k to contractile state changes, contractility was altered through pharmacological interventions. The absolute value of k decreased from 1.354 ± 0.25 (baseline) to 0.685 ± 0.21 after esmolol infusion. The proposed index is sensitive to changes in inotropic state, and has the potential to be used clinically to assess contractile function of patients implanted with VAD.